UnitedHealth: Why This Healthcare Giant Is Mispriced

UnitedHealth (UNH) is facing short-term headwinds, including rising medical costs and CMS model changes, leading to a ~12% reduction in its 2025 EPS guidance; however, the company's long-term growth drivers remain intact, with Medicare Advantage expected to add 800,000 members and Optum Health on track to serve 5.4 million value-based care patients. Despite these challenges, Optum's strong performance, contributing ~43% of UnitedHealth’s operating income, and a current valuation implying significant upside to Street targets suggest a potential re-rating opportunity for the stock.

Analysis

UnitedHealth (UNH) is currently navigating short-term pressures, evidenced by an approximate 12% reduction in its 2025 EPS guidance attributed to unexpected medical cost spikes and disruptions from the CMS V28 model transition. Despite these immediate headwinds, the company's fundamental long-term growth drivers appear intact. Its Medicare Advantage segment demonstrated strong momentum by adding 800,000 members in Q1 FY2025 and is reported to be on pace to serve an additional 800,000 people in FY2025. Furthermore, Optum Health is on track to serve 5.4 million value-based care patients in FY2025, fostering higher-margin, preventive-focused revenue growth. Optum, a significant contributor accounting for approximately 43% of UnitedHealth’s operating income, continues to exhibit robust performance, with Optum Rx achieving 14% topline growth and a $140 billion annual revenue run-rate. The company's shares are trading at a 13x forward P/E and 0.75x sales, a valuation which the article suggests implies a potential 32% upside to average Street targets and indicates a re-rating opportunity as near-term uncertainties subside.

Key Decisions for Investors

• Investors should closely monitor the evolution of medical cost trends and UnitedHealth's adaptation to CMS model changes, as these factors are pivotal for near-term earnings and market sentiment.
• The current stock valuation at a 13x forward P/E, coupled with a reported 32% potential upside to average Street targets, may present a compelling entry point for long-term investors, provided they can look past immediate pressures and focus on the potential for a stock re-rating.
• Focus on the sustained performance of the Optum segment, especially its expansion in value-based care patient numbers and the revenue growth of Optum Rx, as a key indicator of UnitedHealth's capacity to drive higher-margin revenue and uphold its long-term growth narrative.